| Title : Phase 1 and pre-clinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia - Furze_2022_Br.J.Clin.Pharmacol__ |
| Author(s) : Furze RC , Molnar J , Parr NJ , Ahmad F , Henry Y , Howe D , Singh R , Toal M , Bassil AK , Bernard SG , Davis RP , Gibson A , Maller NC , Sharp C , Tough DF , Prinjha RK , Lewis HD |
| Ref : British Journal of Clinical Pharmacology , : , 2022 |
| Abstract : Furze_2022_Br.J.Clin.Pharmacol__ |
| ESTHER : Furze_2022_Br.J.Clin.Pharmacol__ |
| PubMedSearch : Furze_2022_Br.J.Clin.Pharmacol__ |
| PubMedID: 35655123 |
| Title : Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis - Luque-Martin_2019_Front.Pharmacol_10_1242 |
| Author(s) : Luque-Martin R , Van den Bossche J , Furze RC , Neele AE , van der Velden S , Gijbels MJJ , van Roomen C , Bernard SG , de Jonge WJ , Rioja I , Prinjha RK , Lewis HD , Mander PK , de Winther MPJ |
| Ref : Front Pharmacol , 10 :1242 , 2019 |
| Abstract : Luque-Martin_2019_Front.Pharmacol_10_1242 |
| ESTHER : Luque-Martin_2019_Front.Pharmacol_10_1242 |
| PubMedSearch : Luque-Martin_2019_Front.Pharmacol_10_1242 |
| PubMedID: 31736752 |